Journal: Molecular Diagnosis & Therapy
Article Title: Epidermolysis Bullosa: A Review of the Tissue-Engineered Skin Substitutes Used to Treat Wounds
doi: 10.1007/s40291-022-00613-2
Figure Lengend Snippet: Schematic overview of the different components and types of tissue-engineered skin substitutes (TESSs) assessed for epidermolysis bullosa (EB) in clinical studies. To generate TESSs, human skin cells (fibroblasts and/or keratinocytes) are enzymatically isolated from skin biopsies, expanded under different cell culture conditions, and used in conjunction with or without some form of scaffolding material. TESSs have either been developed in house or commercially sourced and can be broadly categorised based on their cellular composition. Epidermal substitutes consist of an epidermal layer of stratified keratinocyte sheets with or without an underlying acellular dermal layer containing scaffolding. Dermal substitutes contain fibroblasts embedded within a scaffolded dermal matrix. Composite substitutes are composed of an epidermal layer of stratified keratinocyte sheets and an underlying scaffolded dermal layer containing fibroblasts. Three commercially sourced TESSs assessed in clinical studies for EB are also shown. Kaloderm® is an epidermal substitute composed of allogeneic keratinocyte sheets. Dermagraft® is a dermal substitute composed of allogeneic fibroblasts cultured within a polyglactin mesh scaffold. Apligraf® is a composite substitute composed of an allogeneic epidermal layer of keratinocytes and an underlying dermal layer consisting of allogeneic fibroblasts. Created with BioRender.com
Article Snippet: For EBS, one group used the commercially available cultured epidermal substitute Kaloderm ® (Tego Science, Seoul, Korea) engineered using keratinocytes derived from neonatal foreskin to cover three large skin lesions on the foot of a paediatric patient [ ].
Techniques: Isolation, Cell Culture, Scaffolding